241 related articles for article (PubMed ID: 28034917)
21. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
[TBL] [Abstract][Full Text] [Related]
22. Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources.
Fitch M; Pang K; Ouellet V; Loiselle C; Alibhai S; Chevalier S; Drachenberg DE; Finelli A; Lattouf JB; Sutcliffe S; So A; Tanguay S; Saad F; Mes-Masson AM
BMC Urol; 2017 Oct; 17(1):98. PubMed ID: 29078772
[TBL] [Abstract][Full Text] [Related]
23. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer - active surveillance as a management option.
Yaxley J; Yaxley J; Gardiner R; Yaxley W
Aust Fam Physician; 2013; 42(1-2):74-6. PubMed ID: 23529468
[TBL] [Abstract][Full Text] [Related]
25. Choosing active surveillance versus curative treatment in a population-based survey of men with low-risk prostate cancer.
Xu J; Janisse J; Goodman M
Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 36696653
[TBL] [Abstract][Full Text] [Related]
26. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
27. The impact of prostate cancer on partners: a qualitative exploration.
Wootten AC; Abbott JM; Osborne D; Austin DW; Klein B; Costello AJ; Murphy DG
Psychooncology; 2014 Nov; 23(11):1252-8. PubMed ID: 24764291
[TBL] [Abstract][Full Text] [Related]
28. User-testing an interactive option grid decision aid for prostate cancer screening: lessons to improve usability.
Scalia P; Durand MA; Faber M; Kremer JA; Song J; Elwyn G
BMJ Open; 2019 May; 9(5):e026748. PubMed ID: 31133587
[TBL] [Abstract][Full Text] [Related]
29. Patient reported factors influencing the decision-making process of men with localised prostate cancer when considering Active Surveillance-A systematic review and thematic synthesis.
Cunningham M; Murphy M; Sweeney P; Richards HL
Psychooncology; 2022 Mar; 31(3):388-404. PubMed ID: 34605104
[TBL] [Abstract][Full Text] [Related]
30. Racial Differences in Treatment Decision-Making for Men with Clinically Localized Prostate Cancer: a Population-Based Study.
Xu J; Janisse J; Ruterbusch J; Ager J; Schwartz KL
J Racial Ethn Health Disparities; 2016 Mar; 3(1):35-45. PubMed ID: 26896103
[TBL] [Abstract][Full Text] [Related]
31. Active Surveillance for Prostate Cancer: How to Do It Right.
Garisto JD; Klotz L
Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
[TBL] [Abstract][Full Text] [Related]
32. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
33. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
34. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
35. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath K; Wessells H
Ann Intern Med; 2012 Apr; 156(8):591-5. PubMed ID: 22351514
[TBL] [Abstract][Full Text] [Related]
36. Patient and disease factors affecting the choice and adherence to active surveillance.
Dall'Era MA
Curr Opin Urol; 2015 May; 25(3):272-6. PubMed ID: 25692724
[TBL] [Abstract][Full Text] [Related]
37. Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.
Donovan JL
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):191-6. PubMed ID: 23271772
[TBL] [Abstract][Full Text] [Related]
38. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
39. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
40. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
